** Shares of biotech firm Oragenics OGEN.A fall 53% to $1.80 premarket
** OGEN is raising up to $20 million through a public offering of preferred stock and warrants
** The offering includes up to 800,000 shares of Series H Convertible Preferred Stock and warrants to buy 800,000 more shares
** Each unit of preferred stock and a warrant is priced at $25
** The preferred stock can be converted into common stock at $2.50/share, a 34.6% discount to the stock's last close
** Co has 715,843 outstanding shares with a market cap of $2.73 million - LSEG
** Co says the proceeds will fund concussion clinical trials, repay a $3 million bridge note, and support general corporate needs
** Dawson James Securities is managing the offering
** As of last close, stock down 65.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。